Introduction Although there have been reports of chemotherapy-induced nausea and
vomiting (CINV) beyond 120 h, its overall prevalence has not been systematically examined …

Introduction Chemotherapy-induced nausea and vomiting (CINV) is a burdensome adverse
event frequently associated with chemotherapy treatment of cancer. Evidence suggests that …

Introduction The aim of this study is to rigorously review the efficacy and safety of olanzapine
in defined hematology oncology settings including (1) the setting of highly emetogenic …

Purpose Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after
chemotherapy, adversely affecting patients' quality of life. Recently, studies have shown …

Purpose Olanzapine-containing regimens have been reported to be effective in preventing
CINV following highly emetogenic chemotherapy (HEC), but it is unsure whether it is cost …

Review the clinical evidence of tropisetron or palonosetron, an old-and new-generation
serotonin (5-hydroxytryptamine) type 3 (5-HT 3) receptor antagonist (RA), respectively, for …

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients
receiving appropriate antiemetic treatment. However, inadequate uptake of current …

An important group of antiemetic drugs used in the treatment of nausea and vomiting after
chemotherapy containing an indole moiety in their structures, working as 5 …

Chemotherapy-induced nausea and vomiting which require multidisciplinary approaches
are among the most common symptoms in children receiving cancer treatment. Despite …

Within the last ten years, there has been a growing body of data on the potential of
neurotransmitter blockers as promising components of comprehensive cancer treatment …